Candesartan

Introduction Overview

Generic Name

candesartan

Brand Name

Atacand

Dosage Form

oral tablet (4 mg; 8 mg; 16 mg; 32 mg)

Drug Class

Angiotensin receptor blockers

Pharmacokinetics

Absorption:
Candesartan is rapidly absorbed following oral administration, with peak plasma concentrations occurring approximately 3 to 4 hours post-dose. The oral bioavailability of candesartan cilexetil is estimated to be approximately 15%, primarily due to extensive first-pass metabolism and incomplete absorption. Food intake does not significantly alter the extent of absorption and can be taken with or without food. Clinical studies have shown that the rate of absorption may be slightly delayed when taken with food, but this does not affect the antihypertensive efficacy.

Distribution:
After absorption, candesartan demonstrates moderate binding to plasma proteins, primarily albumin, at approximately 99%. The volume of distribution is approximately 0.1 L/kg, indicating limited tissue distribution. Candesartan does not extensively cross the blood-brain barrier and its distribution is mainly confined to the systemic circulation and target tissues such as the heart and kidneys where angiotensin II receptors are present.

Metabolism:
Candesartan is administered as a prodrug, candesartan cilexetil, which is rapidly and completely hydrolyzed by esterases in the gastrointestinal tract during absorption to its active form, candesartan. Unlike many cardiovascular agents, further hepatic metabolism is minimal, with candesartan mostly excreted unchanged. The minimal metabolism to inactive metabolites reduces the risk of clinically significant drug interactions through hepatic enzyme modulation.

Elimination:
Candesartan is eliminated primarily via renal (approximately 33%) and fecal (about 67%) routes, largely unchanged. The elimination half-life ranges from 9 to 12 hours, allowing once- or twice-daily dosing for sustained therapeutic effects. Renal impairment may modestly increase candesartan plasma concentrations, but no dosage adjustment is generally required for mild to moderate renal dysfunction. Clearance is not significantly affected by age or mild hepatic impairment; however, caution is advised in severe hepatic impairment due to lack of clinical data. The drug's elimination kinetics support its use in chronic therapy for hypertension and heart failure.

Dosage Forms

Available Dosage Forms:
Candesartan is available exclusively as oral tablets in the following strengths: 4 mg, 8 mg, 16 mg, and 32 mg. This range facilitates flexible dosing adjustments convenient for both initiation and maintenance therapy across different patient needs.

Dosages for Adults and Adolescents:
- Hypertension (Adults): Initial dose is commonly 16 mg orally once daily, with maintenance doses ranging from 8 mg to 32 mg per day, administered in one or two divided doses. The maximum recommended dose is 32 mg per day.
- Heart Failure (Adults): The initial recommended dose is 4 mg once daily, with titration by doubling the dose every two weeks as tolerated to reach a target dose of 32 mg once daily. This dosing corresponds to treatment for New York Heart Association (NYHA) class II-IV heart failure.
- Hypertension (Pediatrics, 1 to <6 years): Initial dose of 0.2 mg/kg/day in one or two divided doses, with maintenance doses ranging from 0.05 to 0.4 mg/kg/day.
- Hypertension (Pediatrics, 6 to <17 years): For children under 50 kg, initial doses are 4 to 8 mg/day, maintenance 2 to 16 mg/day. For children over 50 kg, initial doses are 8 to 16 mg/day, maintenance 4 to 32 mg/day orally in one or two divided doses.

Specific Patient Populations:
- In patients with volume depletion (e.g., those treated with diuretics) or renal impairment, initiate therapy under close medical supervision with consideration of initial dose reduction.
- For pediatric patients unable to swallow tablets, pharmacists may prepare an extemporaneous liquid suspension to facilitate administration.
- No dose adjustments are generally required for elderly patients, but monitoring is advised due to potential for altered pharmacodynamics.
- In hepatic impairment, careful initiation and monitoring are recommended given limited pharmacokinetic data.

Clinical guidelines recommend that candesartan doses be individualized based on clinical response and tolerability. Regular monitoring of blood pressure, renal function, and serum electrolytes is essential during treatment.

Mechanism Of Action

Candesartan is a selective angiotensin II type 1 (AT1) receptor antagonist belonging to the class of angiotensin receptor blockers (ARBs). It competitively inhibits the binding of angiotensin II, a potent vasoconstrictor, to the AT1 receptor sites located on vascular smooth muscle and adrenal glands. This blockade prevents angiotensin II from exerting its physiological effects that contribute to vasoconstriction, aldosterone secretion, sodium retention, and sympathetic nervous system activation.

At the molecular level, candesartan’s antagonism of the AT1 receptor results in vasodilation of the arteries and veins, reduced aldosterone secretion by the adrenal cortex, and diminished sympathetic system activation. These effects collectively lead to decreased peripheral vascular resistance and blood pressure, reduced sodium and water retention, and attenuation of pathological cardiovascular remodeling. Notably, candesartan does not inhibit the angiotensin II type 2 (AT2) receptor, which may have beneficial effects such as vasodilation and antiproliferation.

From a biochemical standpoint, the prodrug candesartan cilexetil is hydrolyzed during absorption to the active candesartan molecule, which binds with high affinity to the AT1 receptor, effectuating sustained receptor blockade due to its slow dissociation kinetics. This pharmacodynamic characteristic enables candesartan to provide stable and prolonged antihypertensive effects with once- or twice-daily dosing.

Clinical studies have demonstrated that by inhibiting the renin-angiotensin-aldosterone system (RAAS), candesartan effectively reduces blood pressure in hypertensive patients and improves morbidity and mortality in patients with heart failure. Compared to angiotensin-converting enzyme (ACE) inhibitors, candesartan offers equivalent efficacy but is less likely to cause cough or angioedema, attributed to its selective ARB action. Research also suggests candesartan may have protective effects against target organ damage, including nephroprotection in diabetic nephropathy and cardiac remodeling in heart failure.

Pharmacological Actions

Selective antagonism of angiotensin II type 1 (AT1) receptors.
Potent vasodilator effect reducing systemic vascular resistance.
Inhibition of aldosterone secretion leading to decreased sodium and water retention.
Reduction of sympathetic nervous system activity.
Lowering of blood pressure in hypertensive patients.
Attenuation of pathological cardiac remodeling and fibrosis.
Improvement of left ventricular function in heart failure.
Reduction of proteinuria in diabetic nephropathy.
Minimal effect on bradykinin metabolism, reducing risk of cough and angioedema.
Stabilization of renal function in patients with chronic kidney disease.
Decrease in oxidative stress and inflammation in vascular tissues.
Good tolerability with minimal central nervous system adverse effects.
Long duration of action allowing once- or twice-daily dosing.
No significant alteration in heart rate at therapeutic doses.

Therapeutic Or Clinical Uses

Treatment of essential hypertension in adults and pediatric patients aged 1 year and older.
Management of heart failure, particularly New York Heart Association (NYHA) class II to IV.
Reduction of cardiovascular morbidity and mortality in patients with heart failure.
Lowering the risk of stroke and myocardial infarction via blood pressure control.
Use as alternative therapy for patients intolerant to ACE inhibitors.
Potential nephroprotective effects in diabetic nephropathy and chronic kidney disease.
Adjunct therapy in managing patients with left ventricular dysfunction.
Control of elevated blood pressure to prevent target organ damage.
Treatment of hypertension in patients on low-salt diets or with volume depletion with caution.
Use in pediatric hypertension to prevent long-term cardiovascular complications.
Prevention of progression of renal impairment in hypertensive patients.
Reduction in hospitalization rates due to heart failure exacerbations.

Side Or Adverse Effects

Hyperkalemia, characterized by elevated serum potassium levels causing weakness, nausea, or arrhythmias.
Dizziness, especially during initial dose titration or volume-depleted states.
Headache frequently reported in treated patients.
Back pain reported in some individuals during therapy.
Upper respiratory symptoms including nasal congestion, runny nose, sneezing, and sore throat.
Abnormal renal function tests including elevated serum creatinine and blood urea nitrogen.
Hypotension and orthostatic dizziness, particularly in volume-depleted or elderly patients.
Fatigue and malaise in some patients.
Potential allergic reactions including rash and, rarely, angioedema.
Gastrointestinal disturbances such as nausea or diarrhea are uncommon.
Rarely, syncope due to excessive blood pressure reduction.
Possible increase in levels of liver enzymes though clinically significant liver injury is rare.
Electrolyte imbalances, particularly when used with potassium-sparing diuretics.
Postural hypotension especially upon standing after prolonged sitting or lying down.

Precautions

Use with caution in patients with volume depletion or those on diuretics due to risk of hypotension.
Monitor serum potassium levels regularly to detect hyperkalemia early.
Assess renal function prior to and during treatment, especially in patients with pre-existing renal impairment.
Avoid concomitant use with aliskiren in patients with diabetes or renal impairment.
Use cautiously in patients with hepatic impairment; close monitoring is advised.
Avoid use during pregnancy; discontinue immediately if pregnancy is detected due to potential fetal harm.
Consider dose adjustment or monitoring during concurrent use with NSAIDs to prevent renal toxicity.
Instruct patients to rise slowly from sitting or lying positions to reduce risk of dizziness and falls.
Avoid potassium supplements or salt substitutes unless directed by a healthcare provider.
Use pediatric formulations or extemporaneous suspensions for children unable to swallow tablets safely.
Regular blood pressure monitoring is essential to ensure therapeutic effectiveness.
Advise patients to report symptoms of angioedema or severe allergic reactions promptly.
Caution in patients with bilateral renal artery stenosis due to risk of acute renal failure.
Patients undergoing surgery should inform anesthesiologists of candesartan use to manage hypotension risks.
Educate patients about the importance of adherence even in the absence of symptoms.

Warnings

Contraindicated during pregnancy due to risk of fetal injury or death; discontinue as soon as pregnancy is detected.
Risk of symptomatic hypotension and renal impairment in volume-depleted patients, especially at treatment initiation.
Co-administration with aliskiren in diabetic patients or those with renal impairment can increase adverse effects.
Potential for hyperkalemia, particularly when used with potassium-sparing diuretics, supplements, or NSAIDs.
Use in patients with severe hepatic impairment not well studied; recommended to avoid or monitor closely.
Risk of angioedema, especially in patients with a history of angioedema or hereditary angioedema.
Caution is advised in elderly patients who are more sensitive to hypotensive effects.
Sudden cessation may lead to rebound hypertension; dose tapering might be necessary in some cases.
NSAIDs may reduce antihypertensive effect and increase risk of renal impairment.
Patients should avoid driving or operating machinery until they know how candesartan affects them due to risk of dizziness.
Potential interactions with lithium leading to increased lithium toxicity; monitor lithium levels closely.
Avoid concomitant use with other agents affecting RAAS without medical supervision.
Use in patients with bilateral renal artery stenosis may result in acute renal failure.
In patients with heart failure, careful dose titration is required to avoid hypotension and renal dysfunction.
Patients should seek immediate medical attention if they experience symptoms of angioedema such as facial swelling or difficulty breathing.

Contraindication

Known hypersensitivity or allergy to candesartan or any component of the formulation.
Pregnancy, especially during second and third trimesters due to teratogenicity and fetal risk.
Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment due to increased adverse reactions.
Bilateral renal artery stenosis or severe renal artery stenosis due to risk of acute renal failure.
Use in breastfeeding is contraindicated due to lack of safety data and potential for neonatal adverse effects.
History of angioedema related to previous treatment with an angiotensin receptor blocker.
Patients with severe hepatic impairment due to altered pharmacokinetics and insufficient safety data.
Concurrent use with potassium-sparing diuretics or potassium supplements without medical supervision in high-risk populations.
Severe hypotension or hemodynamic instability at baseline.
Patients with hypovolemia or significant dehydration prior to correction.
Severe aortic stenosis or patients dependent on the renin-angiotensin system for blood pressure maintenance without close monitoring.
Active liver disease with cholestasis or hepatitis due to potential risk of hepatic toxicity.
Use in pediatric patients below 1 year of age due to insufficient clinical experience and safety data.
Co-administration with ACE inhibitors in conditions where dual blockade poses risk without clinical benefit.
Concurrent use of candesartan with other ARBs or renin inhibitors without specialized medical guidance.

Drug Interactions

Concurrent use with aliskiren in diabetic or renal-impaired patients increases risk of hypotension, hyperkalemia, and renal impairment.
Diuretics enhance the antihypertensive effect but increase risk of hypotension and electrolyte disturbances when combined.
NSAIDs such as ibuprofen and naproxen may reduce antihypertensive effectiveness and impair renal function when used together.
Lithium levels may increase with candesartan co-administration, raising risk of lithium toxicity; monitoring is essential.
Potassium supplements and potassium-sparing diuretics can lead to hyperkalemia when combined with candesartan.
Coadministration with other antihypertensive agents may have additive blood pressure lowering effects, increasing risk of hypotension.
Candesartan’s minimal hepatic metabolism reduces interactions but caution is advised with drugs affecting renal clearance.
Use with non-depolarizing neuromuscular blocking agents may enhance effects, warranting monitoring during anesthesia.
Concomitant use with drugs that impair renal function can exacerbate renal toxicity risks.
Coadministration with CYP450 enzyme inducers or inhibitors has negligible impact due to lack of significant candesartan metabolism via CYP450.
Careful monitoring is required when combining with other agents acting on the renin-angiotensin-aldosterone system to avoid additive adverse effects.
Potential interaction with dual endothelin receptor antagonists which may affect blood pressure regulation.
Combining with certain chemotherapy agents that can cause renal toxicity requires careful renal monitoring.
Concomitant use with sacubitril/valsartan requires careful consideration due to overlapping RAAS blockade effects.
Use with nonsteroidal anti-inflammatory drugs during dehydration or pre-existing renal impairment can precipitate acute renal failure.

Preparations Of The Drug

Oral tablets available in 4 mg strength for initial dosing and titration in heart failure patients.
Oral tablets in 8 mg strength for maintenance therapy and dose escalation in hypertension.
Oral tablets in 16 mg strength commonly used as starting doses for adult hypertension therapy.
Oral tablets in 32 mg strength serving as the maximum recommended dose for severe hypertension and heart failure.
Pharmacist-prepared liquid suspension formulations (extemporaneous) are utilized for pediatric patients unable to swallow tablets.
Medication supplied in blister packs or bottles with dosing instructions and child-resistant packaging.
Each tablet formulation contains candesartan cilexetil as the active ingredient for controlled prodrug conversion.
Formulations are film-coated to facilitate swallowing and improve patient compliance.
Standard storage recommendations include room temperature, protection from moisture and heat to preserve drug stability.
Available brand formulation: Atacand, with proprietary manufacturing and consistent quality control.
Combination therapies incorporating candesartan and diuretics (such as hydrochlorothiazide) are commercially available but not included in this monograph.
Packaging includes detailed patient information leaflets outlining dosing, side effects, and precautions for safe use.
No intravenous or parenteral forms are currently available; the drug is exclusively administered orally.
Generic versions of candesartan tablets exist with similar dosage strengths and pharmacokinetic profiles.
Preparations designed for use in both adult and pediatric patients with appropriate dosing adjustments.